Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 3 天前评分70
正文 · 原文
APEX-Breast01 Rolditamig DXd (TQB2102, a biparatopic ADC) vs TPC chemo in HER2-low MBC has meaningful efficacy
median PFS 16.4 vs 5.5 mo HR=0.29
OS HR=0.44
ORR 68.8% vs 31.0%
#ESMO26
506 浏览 · 7 赞 · 4 转发 · 1 回复
会议摘要
LBA27按 Proffered paper 1: Breast cancer, early and advanced stage 对上
APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study
https://esmocongress.esmo.org帖内回复
- Stephanie Graff, MD, FACP, FASCO@DrSGraff
How to incorporate in complex landscape of ADCs and variability in available treatments internationally remains unclear. #ESMO26
来源：Stephanie Graff, MD, FACP, FASCO · x.com